BASF Pharma Solutions’ Post

🧪  Did you know that Kolliphor® HS 15 can be an alternative to polysorbates for the formulation of biologics?  In biopharmaceutical formulations, surfactants are essential to prevent protein aggregation and ensure therapeutic efficacy. But not all surfactants perform equally well, especially under stress.    At BASF Pharma Solutions, we’re advancing the science of protein stabilization. In the new study “Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical Formulations”, published in Molecular Pharmaceutics, our scientists Felicitas Guth and Nadine Löw, Coralie Schneider, and Matthias Kellermeier, together with experts from Coriolis Pharma, compared the performance of Kolliphor® HS 15 and ELP with conventional surfactants like PS20, PS80, and P188.    🔍 The research explores how these surfactants behave at critical interfaces - air/liquid, oil/water, and solid/liquid - and how they influence antibody aggregation. Silicone oil release and enzymatic degradation was additionally tested. Notably, HS 15 demonstrated strong interfacial activity and promising stabilization performance.    🤝 This publication reflects a strong collaboration between BASF and Coriolis, combining formulation expertise and analytical rigor to support safer, more robust biologics.    📖 Read the full article here:    https://lnkd.in/dXrDNysc    🌐 Explore our excipient solutions: https://pharma.basf.com     #Biopharma #biologics #Pharma #Bioavailability #Antibodies #Research